MedTrace Logo

A Safety and Tolerability Study of BPR-30221616 Injection in Healthy Subjects

NCT06760455 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-02-12

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, tolerability, pharmacokinetics、 pharmacodynamics and immunogenicity of BPR-30221616 in healthy subjects.

Conditions

  • Healthy Participants

Interventions

DRUG

BPR-30221616 Injection

BPR-30221616 will be administered by subcutaneous (SC) injection

DRUG

Sodium Chloride Injection

Sodium Chloride Injection will be administered by SC injection

Sponsors & Collaborators

  • Chengdu Brilliant Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-10
Primary Completion
2026-01-24
Completion
2026-12-05

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06760455 on ClinicalTrials.gov